Editorial Policy & Medical Review Board
Path to Peptides maintains rigorous editorial standards with evidence grading, medical advisory board oversight, and peer-reviewed research to ensure accurate peptide education.
Our Mission
Path to Peptides is an independent research platform dedicated to providing evidence-based peptide education. Our goal is to make complex biomedical research accessible to researchers, clinicians, and informed individuals by synthesizing peer-reviewed literature into clear, structured compound profiles and protocol references.
We do not sell peptides, prescribe treatments, or provide medical advice. Every piece of content on this platform is designed to inform and educate, not to replace the guidance of qualified healthcare professionals.
Editorial Standards
All content published on Path to Peptides follows a rigorous editorial process:
- Research Phase — Compound profiles begin with a comprehensive literature review of peer-reviewed studies, clinical trial data, and established pharmacological references.
- Drafting — Content is written in plain language with full citations. Mechanism-of-action descriptions, dosing ranges cited in literature, and safety considerations are included for every compound.
- Internal Review — Each draft is reviewed for scientific accuracy, balanced presentation of evidence, and clarity. Claims are cross-referenced against original source material.
- Advisory Review — Select profiles undergo additional review by members of our medical advisory board before publication.
- Publication & Monitoring — Published content is monitored for new research developments and updated on a quarterly cycle.
Evidence Grading System
Each compound profile includes an evidence grade reflecting the quality and volume of available research. This helps readers quickly assess how well-studied a given peptide is.
| Grade | Meaning | Criteria |
|---|---|---|
| A | Strong Evidence | Multiple human clinical trials (Phase II+), systematic reviews, or meta-analyses with consistent findings. |
| B | Moderate Evidence | At least one human clinical trial or multiple well-designed animal studies with plausible translational relevance. |
| C | Preliminary Evidence | Primarily animal or in-vitro data. Human evidence limited to case reports, observational studies, or early-phase trials. |
| D | Insufficient Evidence | Very limited published research. May rely on mechanistic rationale, anecdotal reports, or theoretical frameworks. |
Evidence grades are assigned independently of vendor relationships and are never influenced by commercial considerations.
Source Requirements
Path to Peptides maintains strict sourcing standards. Accepted sources include:
- Peer-reviewed journals indexed in PubMed, Scopus, or Web of Science
- Registered clinical trials from ClinicalTrials.gov, WHO ICTRP, or equivalent registries
- Government databases including FDA, EMA, NIH, and WHO publications
- Established pharmacological textbooks and reference works (e.g., Goodman & Gilman's, Martindale)
We do not cite manufacturer marketing materials, social media posts, or unverified anecdotal sources as primary evidence. When community-reported observations are mentioned, they are clearly labeled as anecdotal.
Medical Advisory Board
Our content is guided by an advisory board of specialists with expertise across relevant disciplines. Our advisory board includes specialists in:
- Pharmacology (PhD) — Peptide pharmacokinetics, receptor binding mechanisms, and structure-activity relationships
- Endocrinology (MD) — Hormonal signaling, growth hormone secretagogues, and metabolic peptide research
- Clinical Pharmacy (PharmD) — Drug interactions, reconstitution protocols, and stability considerations
- Biochemistry (MS) — Molecular biology of peptide synthesis, degradation pathways, and bioavailability
Advisory board members review content for scientific accuracy and clinical relevance. Their involvement does not constitute an endorsement of any specific compound, vendor, or use case.
Conflict of Interest Disclosure
Specifically:
- Vendor listings in our Verified Research Suppliers section are clearly identified. These are commercial relationships.
- BioRoot AI and LiveWell Peptides are Official Sponsors of Path to Peptides. Links to BioRoot AI and LiveWell Peptides carry
rel="sponsored"attributes and are clearly labeled. These sponsorships do not influence compound ratings, evidence grades, or editorial conclusions. - Evidence grades, safety ratings, and editorial conclusions are determined solely by our research and advisory review process.
- No vendor or sponsor has the ability to alter, approve, or suppress any content published on this platform.
Content Update Policy
All compound profiles and protocol guides are reviewed quarterly to ensure they reflect the most current published research. Updates may include:
- Incorporation of newly published clinical trial results
- Revisions to evidence grades when significant new data emerges
- Updates to safety considerations or regulatory status changes
- Corrections of factual errors identified through our reporting process
Each compound profile displays a "Last Reviewed" date so readers can assess content currency.
How to Report Errors
We are committed to accuracy and welcome corrections. If you identify a factual error, outdated citation, or misleading statement in any of our content, please contact us:
Email: editorial@pathtopeptides.com
Please include the specific page URL, the statement in question, and any supporting references. We review all submissions and issue corrections within 7 business days when warranted.
